Press release
Generalized Myasthenia Gravis (gMG) Market was valued at USD 2.4 billion in 2024 and is projected to reach USD 6.1 billion by 2034
Generalized Myasthenia Gravis (gMG) Market
The Generalized Myasthenia Gravis (gMG) market was valued at USD 2.4 billion in 2024 and is projected to reach USD 6.1 billion by 2034, growing at a CAGR of around 9.8%. Growth is driven by the rapid adoption of biologics, antibody-targeted therapies, and improved diagnostic awareness for autoimmune neuromuscular disorders.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72089
Key Market Drivers
• Rising global prevalence of autoimmune neuromuscular diseases.
• Strong adoption of complement inhibitors, FcRn inhibitors, and monoclonal antibodies.
• Growing availability of specialty neurology centers and improved treatment guidelines.
• Increased diagnosis through advanced antibody testing (AChR, MuSK, LRP4).
Challenges
• Very high cost of biologic therapies.
• Long-term treatment dependency increases healthcare burden.
• Limited specialist availability in developing regions.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market
Market Segmentation
By Treatment
• Monoclonal antibodies (FcRn & complement inhibitors)
• Immunosuppressants
• Corticosteroids
• Plasma exchange / IVIG
By Diagnosis
• Antibody testing
• Electrophysiology testing
• Imaging / clinical evaluation
By End User
• Hospitals
• Neurology clinics
• Homecare (for maintenance therapies)
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72089
Regional Snapshot
• North America leads due to strong adoption of FcRn and complement inhibitors.
• Europe shows steady growth supported by reimbursement and guideline-based care.
• Asia-Pacific is the fastest-growing region as awareness and biologic access improve.
Key Companies
Alexion (AstraZeneca), Argenx, Roche, Novartis, UCB, Johnson & Johnson, Takeda, Pfizer.
Future Outlook
The market will expand rapidly as new FcRn inhibitors, complement blockers, and next-generation immunotherapies gain approvals. Wider specialist access, earlier diagnosis, and improved affordability models will further drive adoption worldwide.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72089
Our More Reports:
Diamond Blackfan Anemia Market
https://exactitudeconsultancy.com/reports/71277/diamond-blackfan-anemia-market
Fanconi Anemia Market
https://exactitudeconsultancy.com/reports/71277/diamond-blackfan-anemia-market
Hemophilia B Market
https://exactitudeconsultancy.com/reports/71654/hemophilia-b-market
Hepatorenal Syndrome Market
https://exactitudeconsultancy.com/reports/71283/hepatorenal-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generalized Myasthenia Gravis (gMG) Market was valued at USD 2.4 billion in 2024 and is projected to reach USD 6.1 billion by 2034 here
News-ID: 4310985 • Views: …
More Releases from Exactitude Consultancy
Emesis (Anti-Emetic) Market is projected to reach USD 11.92 billion by 2034
The global Emesis Market - focused on drugs and therapies used to prevent and treat nausea and vomiting - was valued at USD 7.46 billion in 2024 and is projected to reach USD 11.92 billion by 2034, growing at a CAGR of 4.9% during the forecast period (2025-2034). Growth is driven by rising incidence of chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), pregnancy-related emesis, motion sickness, gastrointestinal…
Chronic Plaque Psoriasis Market was valued at USD 24.5 billion in 2024 and is pr …
Chronic Plaque Psoriasis Market Overview
The Chronic Plaque Psoriasis Market was valued at USD 24.5 billion in 2024 and is projected to reach USD 43.8 billion by 2034, growing at a CAGR of around 6.2%. Growth is fueled by rising disease prevalence, strong uptake of biologics, and continuous expansion of dermatology specialty care.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71377
Key Market Drivers
• Increasing global prevalence of moderate to severe plaque psoriasis.
• Rapid…
Chronic Liver Disease Market is projected to reach USD 22.31 billion by 2034
The global Chronic Liver Disease (CLD) Market was valued at USD 12.84 billion in 2024 and is projected to reach USD 22.31 billion by 2034, growing at a CAGR of 5.9% from 2025 to 2034. Growth is fueled by increasing global prevalence of liver fibrosis, cirrhosis, viral hepatitis, autoimmune liver diseases, alcohol-related liver disease (ARLD), and metabolic-associated steatotic liver disease (MASLD/MASH). Advances in diagnostic imaging, biomarker-based screening, antifibrotic drug development,…
Birch Allergy Market was valued at USD 1.45 billion in 2024 and is projected to …
The Birch Allergy Market was valued at USD 1.45 billion in 2024 and is projected to reach ~USD 2.62 billion by 2034, growing at a CAGR of around 6.1%. Rising prevalence of seasonal allergies, improved diagnostic awareness, and the increasing use of immunotherapy are the primary factors fueling market growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71309
Key Market Drivers
• Higher incidence of birch pollen allergies in North America and Europe.
• Growing…
More Releases for Generalized
Key Trends Reshaping the Generalized Anxiety Disorder Market: Innovative Drug De …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Generalized Anxiety Disorder Market Size Growth Forecast: What to Expect by 2025?
The market encompassing generalized anxiety disorder has experienced consistent expansion over the preceding years, projected to increase its valuation from $7.76 billion in 2024 to $7.93 billion in the subsequent year, reflecting a compound annual growth rate…
Key Trends Influencing the Growth of the Generalized Anxiety Disorder Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Generalized Anxiety Disorder Market Through 2025?
In recent years, there has been a consistent expansion in the market size for generalized anxiety disorder. The market, which is predicted to grow from $7.76 billion in 2024 to $8.01 billion in 2025, will experience…
Rising Mental Disorder Cases Drive Expansion Of The Generalized Anxiety Disorder …
The Generalized Anxiety Disorder Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Generalized Anxiety Disorder Market Size and Projected Growth Rate?
The market size for generalized anxiety disorder has seen a stable growth in the past few years. The market is expected to…
Key Generalized Anxiety Disorder Market Trend for 2025-2034: Innovative Drug Dev …
"What Is the Future Outlook for the Generalized Anxiety Disorder Market's Size and Growth Rate?
The generalized anxiety disorder market will grow from $7.76 billion in 2024 to $8.01 billion in 2025, at a CAGR of 3.2%. Growth is driven by increased mental health awareness, pharmaceutical advances, the popularity of cognitive-behavioral therapy (CBT), and the stressful lifestyle changes of modern society.
The generalized anxiety disorder market is expected to reach $9.32 billion…
Generalized Anxiety Disorder Market Report and Forecast 2024-2032
Generalized Anxiety Disorder Market Outlook
The generalized anxiety disorder market size in the 7 major markets was valued at USD 1717.5 million in 2023, driven by the increasing advancements in psychotherapeutic as well as pharmacological treatment options for patients. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to rise from USD 1809.8 million in 2024 to USD 2751.1…
Generalized Anxiety Disorder Pipeline Insight Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Generalized Anxiety Disorder Pipeline constitutes 10+ key companies continuously working towards developing 12+ Generalized Anxiety Disorder Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Generalized Anxiety Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Generalized…
